AstraZeneca PLC Notice of AGM (9672T)
March 30 2021 - 06:15AM
UK Regulatory
TIDMAZN
RNS Number : 9672T
AstraZeneca PLC
30 March 2021
30 March 2021 12:15 BST
Notice of Annual General Meeting
AstraZeneca PLC (the Company) announced today the publication of
its Notice of Annual General Meeting 2021 and Shareholders'
Circular (the Notice).
The Notice has been submitted to the National Storage Mechanism
and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism . The Notice
is also available on the Company's website at
www.astrazeneca.com/noticeofmeeting2021
The Company's Annual Report and Form 20-F Information 2020 (the
Annual Report) was published on 15 February 2021.
The Notice is being despatched to shareholders today.
The date of the 2021 Annual General Meeting of the Company (the
AGM) has been changed since the publication of the Annual Report,
which indicated the AGM would take place on 30 April 2021. The AGM
will now be held on Tuesday 11 May 2021 at 11.00am (BST) at Academy
House, 136 Hills Road, Cambridge CB2 8PA. In line with UK
Government restrictions relating to public gatherings as at the
date of the Notice, the AGM will be a closed meeting and it will
not be possible for shareholders to attend.
Shareholders are strongly encouraged to vote in advance of the
meeting by appointing the Chairman of the AGM as their proxy. This
means the Chairman of the AGM will be able to vote on their behalf,
and in accordance with their instructions, at the AGM. Further
details on how shareholders can appoint the Chairman of the AGM as
their proxy can be found on page 10 of the Notice.
The Board values the support and engagement of all shareholders.
On Friday 30 April 2021 at 2.00pm (BST), the Company will
live-broadcast online a presentation from certain members of the
Board and invite shareholders to participate in a live Q&A
session should they wish to do so. Details about how to access the
shareholder engagement event, and how to ask questions can be found
from page 12 of the Notice.
In respect of the proposed acquisition of Alexion
Pharmaceuticals Inc. (the Transaction), a separate Notice of
Meeting and Shareholders' Circular will be published and despatched
to shareholders in due course in connection with the shareholders'
general meeting at which approval to proceed with the Transaction
will be sought.
The Company continues to monitor the situation in relation to
COVID-19 and will notify shareholders via our website,
www.astrazeneca.com as soon as practicably possible if there are
any changes to the AGM arrangements.
The business to be conducted at the AGM is summarised below:
1. To receive the Company's Accounts, the Reports of the
Directors and Auditor and the Strategic Report for the year ended
31 December 2020
2. To confirm dividends
3. To reappoint PricewaterhouseCoopers LLP as Auditor
4. To authorise the Directors to agree the remuneration of the
Auditor
5. To elect or re-elect Directors
6. To approve the Annual Report on Remuneration for the year
ended 31 December 2020
7. To approve the Directors' Remuneration Policy
8. To authorise limited political donations
9. To authorise the Directors to allot shares
10. To authorise the Directors to disapply pre-emption
rights
11. To authorise the Directors to further disapply pre-emption
rights for acquisitions and specified capital investments
12. To authorise the Company to purchase its own shares
13. To reduce the notice period for general meetings
14. To amend the rules of the Performance Share Plan 2020
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @ AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAWPUUPWUPGGUU
(END) Dow Jones Newswires
March 30, 2021 07:15 ET (11:15 GMT)
Astrazeneca (LSE:0A4J)
Historical Stock Chart
From Feb 2024 to Mar 2024
Astrazeneca (LSE:0A4J)
Historical Stock Chart
From Mar 2023 to Mar 2024